-

Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it will report its first quarter 2025 financial results on Thursday, May 15, 2025.

In connection with the earnings release, Gossamer’s management team will host a live conference call and webcast at 4:30 p.m. ET on Thursday, May 15, 2025, to discuss the Company’s financial results and provide a corporate update.

Domestic Dial-in Number: (800) 285-6670
International Dial-in Number: (713) 481-0091
Live Webcast: https://edge.media-server.com/mmc/p/m5ahx8qm

A replay of the audio webcast will be available for 30 days on the Investors section of the Company's website, www.gossamerbio.com.

About Gossamer Bio

Gossamer Bio is a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.

Contacts

For Investors and Media:
Bryan Giraudo, Chief Financial Officer & Chief Operating Officer
Gossamer Bio Investor Relations
ir@gossamerbio.com

Industry:

Gossamer Bio, Inc.

NASDAQ:GOSS
Release Versions
English
$Cashtags
$GOSS

Contacts

For Investors and Media:
Bryan Giraudo, Chief Financial Officer & Chief Operating Officer
Gossamer Bio Investor Relations
ir@gossamerbio.com

More News From Gossamer Bio, Inc.

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant, effective June 5th, 2025, to three non-executive employees of non-qualified stock op...

Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the first quarter ended March 31, 2025, and announced the closure of new patient screening for the ongoing registrational Phase 3 PROSERA Study...

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant, effective May 5, 2025, to three non-executive employees of non-qualified stock optio...
Back to Newsroom